Market Cap : 1.41 B | Enterprise Value : 1.21 B | PE Ratio : At Loss | PB Ratio : 4.17 |
---|
NAS:ENTA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:ENTA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Enanta Pharmaceuticals has the Profitability Rank of 7.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1. Operating Margin %Enanta Pharmaceuticals's Operating Margin % for the quarter that ended in Jun. 2022 was -167.05%. As of today, Enanta Pharmaceuticals's Piotroski F-Score is 3.
For the Biotechnology subindustry, Enanta Pharmaceuticals's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Enanta Pharmaceuticals's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Enanta Pharmaceuticals's Profitability Rank falls into.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
Enanta Pharmaceuticals has the Profitability Rank of 7.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Enanta Pharmaceuticals's Operating Margin % for the quarter that ended in Jun. 2022 is calculated as:
Operating Margin % | = | Operating Income (Q: Jun. 2022 ) | / | Revenue (Q: Jun. 2022 ) |
= | -32.54 | / | 19.479 | |
= | -167.05 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Warning Sign:
Piotroski F-Score of 3 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
Enanta Pharmaceuticals has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
Thank you for viewing the detailed overview of Enanta Pharmaceuticals's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Russell Lesley | director | 41 MOORES RD. FRAZER PA 19355 |
Peterson Kristine | director | AMARIN CORPORATION MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE MYSTIC CT 06355 |
Foletta Mark G | director | AMYLIN PHARMACEUTICALS INC 9360 TOWNE CENTRE DR SAN DIEGO CA 92121 |
Hata Yujiro S | director | C/O XENCOR, INC. 111 WEST LEMON AVENUE MONROVIA CA 91016 |
Luu Brendan | officer: Sr. VP, Business Dev. | C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET WATERTOWN MA 02472 |
Kieffer Tara Lynn | officer: Sr. VP, New Product Dev. | C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET WATERTOWN MA 02472 |
Adda Nathalie | officer: Sr. VP & Chief Medical Officer | C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET WATERTOWN MA 02472 |
Gardiner Nathaniel S. | director | C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET WATERTOWN MA 02472 |
Golumbeski George | director | C/O CELGENE CORP. 86 MORRIS AVENUE SUMMIT NJ 07901 |
Ocain Tim | officer: Senior Vice President | C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET WATERTOWN MA 02472 |
Carter Bruce L A | director | C/O ZYMOGENETICS, INC. 1201 EASTLAKE AVENUE SEATTLE WA 98102 |
Saints Capital Granite, L.p. | 10 percent owner | 475 SANSOME STREET SUITE 1850 SAN FRANCISCO CA 94111 |
Saints Capital Granite, Llc | 10 percent owner | 475 SANSOME STREET, SUITE 1850 SAN FRANCISCO CA 94111 |
Obp (bermuda) Iii - Holdings Llc | 10 percent owner | 475 SANSOME STREET, SUITE 1850 SAN FRANCISCO CA 94111 |
Mrna - Holdings Llc | 10 percent owner | 475 SANSOME STREET, SUITE 1850 SAN FRANCISCO CA 94111 |
From GuruFocus
Other Sources
By Zacks 2021-10-20
By Zacks 2021-10-08
By Seekingalpha 2021-03-08
By Seekingalpha 2021-02-08
By tipranks.com 2022-02-13
By tipranks.com 2022-02-26
By Seekingalpha 2022-02-08
By Zacks 2021-11-04
By Zacks 2022-02-07
By tipranks.com 2022-03-11
By Zacks 2021-05-06
By Zacks 2021-11-19